Entrada Therapeutics Inc (TRDA)

Jun 10, 2026, 9:30 AM EDT - 14 days ago

Entrada Therapeutics Transcript: AGM 2026

Jun 8, 2026, 8:00 AM EDT - 16 days ago

Entrada Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-08T11:22:58.000Z - 16 days ago

Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim

Jun 8, 2026, 7:00 AM EDT - 16 days ago

Entrada Therapeutics Slides: Corporate presentation

Jun 3, 2026, 5:30 PM EDT - 21 days ago

Entrada Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 7:00 AM EDT - 22 days ago

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study

Jun 1, 2026, 4:30 PM EDT - 23 days ago

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 19, 2026, 10:00 AM EDT - 5 weeks ago

Entrada Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 11, 2026, 10:40 AM EDT - 6 weeks ago

Entrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-05-08T19:22:05.000Z - 6 weeks ago

Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital

NVS

2026-05-08T10:33:55.000Z - 6 weeks ago

Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

2026-05-07T18:55:28.000Z - 6 weeks ago

Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study

2026-05-07T12:38:27.000Z - 6 weeks ago

Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)

May 7, 2026, 8:30 AM EDT - 6 weeks ago

Entrada Therapeutics Transcript: Study result

May 7, 2026, 8:30 AM EDT - 6 weeks ago

Entrada Therapeutics Press release: Study result

May 7, 2026, 8:30 AM EDT - 6 weeks ago

Entrada Therapeutics Slides: Study result

May 7, 2026, 7:10 AM EDT - 6 weeks ago

Entrada Therapeutics Reports First Quarter 2026 Financial Results

May 7, 2026, 7:04 AM EDT - 6 weeks ago

Entrada's Duchenne drug shown to improve muscle function in early trial

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Entrada Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Entrada Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 7 weeks ago

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Entrada Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Entrada Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Entrada Therapeutics Proxy statement: Proxy filing

2026-04-06T12:05:42.000Z - 2 months ago

Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer

2026-04-01T11:04:15.000Z - 3 months ago

Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-04-01T10:34:05.000Z - 3 months ago

Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-03-30T15:35:39.000Z - 3 months ago

Entrada Therapeutics management to meet with Oppenheimer

Mar 3, 2026, 2:30 PM EST - 4 months ago

Entrada Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-27T12:54:27.000Z - 4 months ago

Entrada Therapeutics price target raised to $19 from $13 at Roth Capital

2026-02-26T12:07:36.000Z - 4 months ago

Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)

Feb 26, 2026, 7:00 AM EST - 4 months ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 7:00 AM EST - 4 months ago

Entrada Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 4 months ago

Entrada Therapeutics Annual report: Q4 2025

2026-02-17T12:10:30.000Z - 4 months ago

Entrada announces DMC recommends initiation of Cohort 2 in ELEVATE-44-201 study

Feb 17, 2026, 7:00 AM EST - 4 months ago

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study

Feb 11, 2026, 4:00 PM EST - 4 months ago

Entrada Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-02-11T11:10:24.000Z - 4 months ago

Entrada Therapeutics initiated with a Buy at Guggenheim

2026-02-10T21:27:46.000Z - 4 months ago

Entrada Therapeutics initiated with a Buy at Guggenheim

Feb 4, 2026, 7:00 AM EST - 5 months ago

Entrada Therapeutics to Present at Upcoming Investor Conferences

2026-01-28T12:35:11.000Z - 5 months ago

Entrada Therapeutics initiated with an Outperform at Oppenheimer

Jan 14, 2026, 6:45 PM EST - 5 months ago

Entrada Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 5 months ago

Entrada Therapeutics Slides: Corporate presentation

2026-01-08T12:16:10.000Z - 5 months ago

Entrada Therapeutics reports progress across development portfolio

Jan 8, 2026, 7:00 AM EST - 5 months ago

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

Dec 17, 2025, 7:00 AM EST - 6 months ago

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-11-06T23:40:23.000Z - 8 months ago

Entrada Therapeutics price target lowered to $13 from $17 at Roth Capital

2025-11-06T12:50:18.000Z - 8 months ago

Entrada Therapeutics files $400M mixed securities shelf

2025-11-06T12:16:45.000Z - 8 months ago

Entrada Therapeutics reports Q3 EPS ($1.06), consensus (96c)

Nov 6, 2025, 7:00 AM EST - 8 months ago

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 7:00 AM EST - 8 months ago

Entrada Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Entrada Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Entrada Therapeutics Registration statement: Registration Filing

Sep 25, 2025, 10:00 AM EDT - 9 months ago

Entrada Therapeutics Transcript: H.C.Wainwright @ Home Fireside Chat

Sep 25, 2025, 7:00 AM EDT - 9 months ago

Entrada Therapeutics Slides: International Conference on Muscle Wasting Presentation

Sep 8, 2025, 7:00 AM EDT - 10 months ago

Entrada Therapeutics Slides: Corporate Presentation

Sep 5, 2025, 7:00 AM EDT - 10 months ago

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

Aug 18, 2025, 7:00 AM EDT - 11 months ago

Entrada Therapeutics Slides: FY 2025

Aug 6, 2025, 7:00 AM EDT - 11 months ago

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 11 months ago

Entrada Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 7:00 AM EDT - 11 months ago

Entrada Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 7:00 AM EDT - 11 months ago

Entrada Therapeutics Slides: Q2 2025

Jul 21, 2025, 2:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: 6th International Caparica Conference on Splicing Presentation

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Entrada Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 11:05 AM EDT - 1 year ago

Entrada Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 12:00 PM EDT - 1 year ago

Entrada Therapeutics Slides: Corporate Presentation

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Entrada Therapeutics Proxy statement: Proxy Filing

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

BIIB

May 28, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 22, 2025, 2:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: FY 2025

May 20, 2025, 2:00 PM EDT - 1 year ago

Entrada Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 14, 2025, 2:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: 28th Annual ASGCT Meeting Presentation

May 8, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 7, 2025, 6:00 PM EDT - 1 year ago

Entrada Therapeutics Earnings release: Q1 2025

May 7, 2025, 6:00 PM EDT - 1 year ago

Entrada Therapeutics Quarterly report: Q1 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 3, 2025, 2:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: 2nd Peptide-Based Therapeutics Summit Presentation

Mar 26, 2025, 3:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: 4th Novel Conjugates Summit Presentation

Mar 26, 2025, 3:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: FY 2025

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Feb 27, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Annual report: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Slides: Q4 2024

Feb 24, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Feb 3, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Jan 30, 2025, 4:05 PM EST - 1 year ago

Azenta Announces the Election of Dipal Doshi to its Board of Directors

AZTA

Jan 15, 2025, 2:15 PM EST - 1 year ago

Entrada Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 2:15 PM EST - 1 year ago

Entrada Therapeutics Slides: FY 2025

Dec 18, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 12:30 PM EST - 1 year ago

Entrada Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 5, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics Earnings release: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics Slides: Q3 2024

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Sep 24, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Sep 17, 2024, 8:30 AM EDT - 1 year ago

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

Sep 9, 2024, 12:30 PM EDT - 1 year ago

Entrada Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Slides: Corporate Presentation

Jun 24, 2024, 7:15 AM EDT - 2 years ago

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Jun 24, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Slides: Corporate Presentation

Jun 24, 2024, 6:00 AM EDT - 2 years ago

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

Jun 10, 2024, 4:00 PM EDT - 2 years ago

Entrada Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 16, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 7, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports First Quarter 2024 Financial Results

May 7, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Quarterly report: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Earnings release: Q1 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Entrada Therapeutics Proxy statement: Proxy Filing

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Entrada Therapeutics Earnings release: Q4 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Entrada Therapeutics Annual report: Q4 2023

Mar 13, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Nov 22, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

Nov 7, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics Quarterly report: Q3 2023

Nov 7, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics Earnings release: Q3 2023

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

Aug 8, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

Aug 8, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Quarterly report: Q2 2023

Aug 8, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Earnings release: Q2 2023

Jun 14, 2023, 1:40 PM EDT - 3 years ago

Entrada Therapeutics Transcript: Goldman Sachs 44th Annual Global Healthcare Conference

Jun 6, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

May 10, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports First Quarter 2023 Financial Results

May 10, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Quarterly report: Q1 2023

May 10, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Earnings release: Q1 2023

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 4, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

Mar 29, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

Mar 6, 2023, 7:00 AM EST - 3 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 6, 2023, 7:00 AM EST - 3 years ago

Entrada Therapeutics Earnings release: Q4 2022

Mar 6, 2023, 7:00 AM EST - 3 years ago

Entrada Therapeutics Annual report: Q4 2022

Feb 27, 2023, 7:00 AM EST - 3 years ago

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference